Regeneron's 'Champion Of Cancer Vaccines' Forges New Path

An Interview With Raquel Deering, Associate Director Of Immuno-Oncology At Regeneron

Raquel Deering, one of In Vivo's 2020 Rising Leaders, discusses Regeneron's efforts to develop combination therapies, its collaborations with cancer vaccine companies, and its plans to become a major force in the oncology field.

Magnifying lens over background with text Immuno-oncology, with the blurred lights visible in the background. 3D rendering.
• Source: Shutterstock

Raquel Deering knew she wanted to be a scientist as a young child. When she was 14, she called Paige Kaplan, a medical geneticist at The Children's Hospital of Philadelphia, and asked to visit to talk about her work. Kaplan agreed and was so impressed with Deering she took her on as an intern. For several years, Deering worked with a clinical fellow in a lab at the University of Pennsylvania and did clinical rounds with Kaplan at the hospital.

"Those super early influences in science were probably the most important," Deering said in an interview. "Science and math can be hard and dry when you're young

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from C-Suite Speaks

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By 

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By 

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

More from Leadership